Skip to content

The effect of taking sumac fruit powder capsules on menstrual pain and fatigue in women of reproductive age

Comparison of the effects of consuming sumac fruit powder capsules with meflamic acid capsules on menstrual pain and fatigue in women of reproductive age

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251016067648N1
Enrollment
90
Registered
2025-12-15
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Menstrual pain. Condition 2: Fatigue. Pain and other conditions associated with female genital organs and menstrual cycle Other fatigue

Interventions

Intervention 1: First intervention group: The first menstrual cycle received 250 mg mefenamic acid capsules, the second cycle received 1 gram sumac capsules, and in the third month received 1 gram sum

Sponsors

Gonabad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Women aged 18 to 30 years Body mass index is 18.19 to 29. Moderate (4-7) or severe (8-10) dysmenorrhea for at least one day out of the first three days of menstruation without taking medication in three consecutive cycles before the start of the study, according to the score obtained from the pain severity assessment tool. Having a regular menstrual cycle (21-35), duration of normal bleeding (3-7), and volume of normal bleeding according to the individual's statement, history, and examination by the therapist.

Exclusion criteria

Exclusion criteria: Sumac allergy self-reported Pregnancy and childbirth history Medical conditions including thyroid disorders, diabetes, endometriosis, ovarian cysts, uterine fibroids, glandular disorders, polycystic ovary, primary or secondary amenorrhea, cancer, cardiovascular, kidney and liver, and urinary and genital infections, as stated by the individual and medical records, and examination by the therapist and ultrasound. History of surgery on the uterus and ovaries Undergoing infertility treatment Medication use of aspirin, warfarin, heparin, and tranexamic acid as reported by the individual and in the medical record

Design outcomes

Primary

MeasureTime frame
Pain score after receiving interventions. Timepoint: In three stages, pain scores are measured during the first three days of menstruation for each group. Method of measurement: To measure pain intensity, a standard 100 mm VAS tool, whose validity has been previously determined, will be used, and pain intensity will be measured using a graduated ruler, with a score of 10 representing the most severe pain and a score of 0 representing no pain.;Fatigue score. Timepoint: In three stages, pain scores are measured during the first three days of menstruation for each group. Method of measurement: Multidimensional Fatigue Index (MFI).

Secondary

MeasureTime frame
Mouse Menstrual Distress Questionnaire Score. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: Mouse Questionnaire.;Amount of menstrual bleeding. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: Higham Chart or PBAC Blood Loss Assessment Chart.;Energy received. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: 24-hour recall questionnaire.;Protein intake. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: 24-hour recall questionnaire.;Carbohydrate intake. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: 24-hour recall questionnaire.;Fat intake. Timepoint: It will be done every three months on the first three days of menstruation. Method of measurement: 24-hour recall questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasol Rahmani Bailandi

Tabriz University of Medical Sciences

rasolrahmani2020@gmail.com+98 51 5722 5666

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026